Oncothyreon Inc. Overview

State:Washington
Country:United States
Industry:Biotechnology and Drugs
Description:
Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company. The Company focuses primarily on the development of therapeutic products for the treatment of cancer. Oncothyreon’s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. The Company’s lead product candidate under clinical development is a vaccine it calls Stimuvax. Stimuvax incorporates a 25 amino acid sequence of the cancer antigen MUC1, in a liposomal formulation. Stimuvax is designed to induce an immune response to destroy cancer cells that express MUC1, a protein antigen widely expressed on many common cancers, such as lung cancer, breast cancer and colorectal cancer. Oncothyreon has granted an exclusive,... (More)

Get Trial Access to OneSource

Company profiles, executive contacts, industry research, and news for sales, marketing and research professionals.

Disclaimer: While the OneSource Subscription Service maintains the freshest, most accurate data possible, this free site is refreshed on a periodic basis and may occasionally contain information that is not current. If you would like to alert us to a change, please email us, and we will take steps to make sure your update is included as soon as possible

Oncothyreon Inc. Overview

Get Trial Access to OneSource

Business Information

Executive Profiles

Company Lists